Clinical trialNCT02708680CompletedPhase 1/PHASE2Interventional

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

SponsorSyndax PharmaceuticalsEnrollment89Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with atezolizumab in participants with Advanced Triple Negative Breast Cancer (aTNBC). Additionally, the purpose of the study is to assess how effective entinostat and atezolizumab are in combination in participants with aTNBC.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Dennis Slamon, MD
University of California, Los Angeles
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia

Cancer Center of Adjara Autonomous Republic
Batumi, Adjara, Georgia
Saint Nikolozi Surgery and Oncological Centre
Kutaisi, Imereti, Georgia
Unimed Adjara - Oncology Center
Kutaisi, Imereti, Georgia
Cancer Research Center
Tbilisi, Georgia
Health House
Tbilisi, Georgia
Institute of Clinical Oncology
Tbilisi, Georgia
Multiprofile Clinic Consilium Medulla
Tbilisi, Georgia
New Vision University Hospital
Tbilisi, Georgia
Research Institute of Clinical Medicine
Tbilisi, Georgia
S. Khechinashvili, University Hospital
Tbilisi, Georgia

United States

Uab Comprehensive Cancer Center
Birmingham, Alabama, United States
Cbcc Global Research at Comprehensive Blood and Cancer Center
Bakersfield, California, United States
St. Jude Medical Center
Fullerton, California, United States
Los Angeles Hematology Oncology Medical Group
Glendale, California, United States
Torrance Memorial Cancer Care Associates
Redondo Beach, California, United States
Slo Oncology and Hematology Health Center
San Luis Obispo, California, United States
Central Coast Medical Oncology Group
Santa Maria, California, United States
Ucla Hematology/oncology - Santa Monica
Santa Monica, California, United States
Saint Mary'S Regional Cancer Center
Grand Junction, Colorado, United States
Office of Human Research
Hollywood, Florida, United States
Orlando Health, Inc.
Orlando, Florida, United States
Ft. Wayne Hematology and Oncology
Fort Wayne, Indiana, United States
Ft. Wayne Medical Oncology & Hematology, Inc
Fort Wayne, Indiana, United States
Cancer Center of Kansas
Wichita, Kansas, United States
Frauenshuh Cancer Center at Park Nicollet Health Service
Saint Louis Park, Minnesota, United States
Saint Barnabas Medical Cancer Center
Livingston, New Jersey, United States
Hope Women'S Cancer Centers
Asheville, North Carolina, United States
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →EntinostatPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2016
Primary completion: 31 Mar 2021
Completion: 31 Mar 2021
Last update posted: 4 Dec 2024
Registered enrollment: 89
Registry id: NCT02708680

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.